https://www.urologytimes.com/view/adjuvant-atezolizumab-falls-short-in-renal-cell-carcinoma
0
0
9/11/22 at 2:06am
Organization
Urologytimes.com
Author
Jason M. Broderick
34 words
0
Comments
The double-blind phase 3 IMmotion010 trial randomized patients with resected renal cell carcinoma at increased risk of recurrence to adjuvant atezolizumab or placebo.
You are the first to view
Create an account
or login to join the discussion